Healthcare

AbbVie reported third-quarter 2026 net revenue of USD 17.404 billion, up 10.3% on a reported basis. Its immunology portfolio generated USD 9.165 billion, increasing 16.3% year-on-year. Skyrizi revenue reached USD 5.776 billion and Rinvoq produced USD 2.706 billion. Humira contributed USD 683 million, lower …

Eli Lilly recorded third-quarter 2026 revenue of USD 24.4 billion, up 39% against the preceding year. Growth was led primarily byDemandfor Mounjaro and Zepbound.

For the third quarter of 2026, Moderna reported approximately USD 1.3 billion in revenue, GAAP net income of approximately USD 0.2 billion and GAAPDiluted Earnings per Shareof USD 0.38. These results are for the September-ending quarter, not a full-year period.

After reports of mild to moderate skin irritation in some patients, the company decided to pause recruitment. The pause allows a review of unblinded data from patients who have completed the study and those still enrolled. Only after that review will Syntara decide whether …

The company implanted the WiSE system in 40 commercial patients during the quarter, taking total commercial implants across the pilot launch phase and limited market release to 157. Monthly cases in September were roughly half the average recorded in July and August. During the …

Under the agreement, EVE supplies its patent-pending nano-emulsion technology, technical know-how and commercial support. Optimal is responsible for sourcing ingredients, compounding, dispensing and delivering the product. Profit available for distribution is shared 75 per cent to EVE and 25 per cent to Optimal. That …

Biome reported FY26 sales revenue of A$23.88 million, up 30% from A$18.42 million.Gross Profitrose 33%, EBITDA excluding share-based payments climbed 115%, and net profit before tax rose 453% to A$1.19 million. Net profit after tax was A$3.61 million, which included a non-cash deferred tax …